- £218.75bn
- £236.77bn
- $54.07bn
- 78
- 14
- 98
- 73
REG - JPMorgan Elect PLC JPMorgan Elect-JPEI JPMorgan Elect PLC . - Ten Largest Investments
AnnouncementREG - AstraZeneca PLC - Update on Epanova Phase III STRENGTH trial
AnnouncementREG - AstraZeneca PLC - Lynparza granted FDA Priority Review for PAOLA-1
AnnouncementREG - Law Debenture Corp - Net Asset Value and Portfolio Update
AnnouncementREG - AstraZeneca PLC - Lokelma approved in China for hyperkalaemia
AnnouncementREG - AstraZeneca PLC - Farxiga granted FDA heart failure Priority Review
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - US FDA approved Lynparza for pancreatic cancer
AnnouncementREG - AstraZeneca PLC - Enhertu (trastuzumab deruxtecan) approved in US
AnnouncementREG - AstraZeneca PLC - Triple-combination approved in China for COPD
AnnouncementREG - AstraZeneca PLC - AstraZeneca divests rights to Arimidex and Casodex
AnnouncementREG - AstraZeneca PLC - FDA panel backs Lynparza use for pancreatic cancer
AnnouncementREG - AstraZeneca PLC - Seroquel rights agreement complete: Europe, Russia
AnnouncementREG - AstraZeneca PLC - Imfinzi approved in China for Stage III NSCLC
AnnouncementREG - JPMorgan Elect PLC JPMorgan Elect-JPEI JPMorgan Elect PLC . - Ten Largest Investments
AnnouncementREG - AstraZeneca PLC - Trastuzumab deruxtecan achieves ORR of 60.9%
AnnouncementREG - AstraZeneca PLC - Lynparza approved in China for 1L BRCAm ovarian
AnnouncementREG - AstraZeneca PLC - AstraZeneca divests Seroquel rights: US and Canada
AnnouncementREG - AstraZeneca PLC - Block listing Interim Review
Announcement